HemaMax™, a Recombinant Human Interleukin-12, Is a Potent Mitigator of Acute Radiation Injury in Mice and Non-Human Primates
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. This study investigated pharmacokinetics, pharmacodynamics, and efficacy of m-HemaMax (recombinant murine IL-12), and HemaMax to increase survival after total body irradiation (TBI) in mice and rhesus monkeys, respectively, with no supportive care. In mice, m-HemaMax at an optimal 20 ng/mouse dose significantly increased percent survival and survival time when administered 24 hours after TBI between 8-9 Gy (p<0.05 Pearson's chi-square test). This survival benefit was accompanied by increases in plasma interferon-γ (IFN-γ) and erythropoietin levels, recovery of femoral bone hematopoiesis characterized with the presence of IL-12 receptor β2 subunit-expressing myeloid progenitors, megakaryocytes, and osteoblasts. Mitigation of jejunal radiation damage was also examined. At allometrically equivalent doses, HemaMax showed similar pharmacokinetics in rhesus monkeys compared to m-HemaMax in mice, but more robustly increased plasma IFN-γ levels. HemaMax also increased plasma erythropoietin, IL-15, IL-18, and neopterin levels. At non-human primate doses pharmacologically equivalent to murine doses, HemaMax (100 ng/Kg and 250 ng/Kg) administered at 24 hours after TBI (6.7 Gy/LD(50/30)) significantly increased percent survival of HemaMax groups compared to vehicle (p<0.05 Pearson's chi-square test). This survival benefit was accompanied by a significantly higher leukocyte (neutrophils and lymphocytes), thrombocyte, and reticulocyte counts during nadir (days 12-14) and significantly less weight loss at day 12 compared to vehicle. These findings indicate successful interspecies dose conversion and provide proof of concept that HemaMax increases survival in irradiated rhesus monkeys by promoting hematopoiesis and recovery of immune functions and possibly gastrointestinal functions, likely through a network of interactions involving dendritic cells, osteoblasts, and soluble factors such as IL-12, IFN-γ, and cytoprotectant erythropoietin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lgr5+ve Stem Cells Drive Self-Renewal in the Stomach and Build Long-Lived Gastric Units In Vitro
Barker, N., Huch, M., Kujala, P., van de Wetering, M., Snippert, H. J., van Es, J. H., Sato, T., Stange, D. E., Begthel, H., van den Born, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.013 · Cited by 1,547
Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
Emerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
Erythropoietin: A Potent Inducer of Peripheral Immuno/Inflammatory Modulation in Autoimmune EAE
Yuan, R., Maeda, Y., Li, W., Lu, W., Cook, S., & Dowling, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001924 · Cited by 94 · cited 3×
“shown to suppress the inflammatory response related to IFN-c in an animal model of multiple sclerosis [29].”
BackgroundInfluential
Cited by
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
“Combining radiotherapy and IL-12 may also have additional advantage as IL-12 could not only potentiate antitumor effects of radiotherapy [71] but could diminish acute radiotherapy injury, according to observation in non-human primates [83].”
BackgroundShedding new light on neurodegenerative diseases through the mammalian target of rapamycin
Chong, Z. Z., Shang, Y. C., Wang, S., & Maiese, K. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.001 · Cited by 119
“Oxidative stress that impairs mTOR signaling not only may lead to acute or chronic cell injury (Basile et al., 2012; Chalkias and Xanthos, 2012; Maiese et al., 2009e; Yoo et al., 2012), but also lead to changes in metabolism and cell longevity (Chong et al.”
BackgroundSingh, V. K., & Seed, T. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1969054 · Cited by 88
“The efficacy of FGF-C to either protect (via prophylaxis) or to mitigate (24 h post-exposure treatments with 10 lg of drug without additional exogenous heparin treatments) acute radiation injury of the gastrointestinal system (i.e. GI-ARS) of mice (BALB/C mice; 8–12Gy TBI) was assessed in terms of GI crypt structure a…”
BackgroundMethodInfluentialGluzman‐Poltorak, Z., Vainstein, V., & Basile, L. A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23770 · Cited by 48
Self-citation
Metadata
- Authors
- Basile, L. A., Ellefson, D., Gluzman-Poltorak, Z., Junes-Gill, K., Mar, V., Mendonca, S., Miller, J. D., Tom, J., Trinh, A., & Gallaher, T. K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-02-24
- Volume
- 7
- Issue
- 2
- Pages
- e30434
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1979775113
- Cited by
- 64
- References
- 5
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.